peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GLP-1/glucagon dual agonist

Pemvidutide

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

Pemvidutide activates both GLP-1 and glucagon receptors (dual agonism). Pemvidutide acts as a dual agonist at GLP-1 and glucagon receptors. On pemvidutide 1.8 mg, about half of participants achieved MRI-defined liver fat normalization (≤5%) by week 24.

Sources for this introduction: [1] [2] [3]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Pemvidutide activates both GLP-1 and glucagon receptors (dual agonism).

Sources[1]pubmedSafety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.This was a double-blind 12-week extension of a randomized, placebo-controlled, 12-week trial of pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “This was a double-blind 12-week extension of a randomized, placebo-controlled, 12-week trial of pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).”

    Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. · BACKGROUND & AIMS

    pubmed:41113119:e0f89798b5ff:e0f89798b5ff

How does it work?

Target, response, and disposition.

Mechanism

Pemvidutide acts as a dual agonist at GLP-1 and glucagon receptors.

Sources[2]pubmedSafety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.GLP-1-glucagon dual receptor agonists such as pemvidutide[3]pubmedEfficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.Pemvidutide, a dual GLP-1/glucagon receptor agonist,
Source records
2
Independent studies
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “GLP-1-glucagon dual receptor agonists such as pemvidutide”

    Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. · BACKGROUND

    pubmed:41237796:3813636288cf:3813636288cf
  2. supports · Source-backed record
    “Pemvidutide, a dual GLP-1/glucagon receptor agonist,”

    Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials. · Abstract

    pubmed:41879841:2c17d37ab924:2c17d37ab924

What has been studied?

What the evidence says.

Study findings

On pemvidutide 1.8 mg, about half of participants achieved MRI-defined liver fat normalization (≤5%) by week 24.

Sources[1]pubmedSafety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.and 53.8% achieving normalization (≤5% liver fat content) at the 1.8 mg dose.
Reported result
53.8%
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “and 53.8% achieving normalization (≤5% liver fat content) at the 1.8 mg dose.”

    Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. · RESULTS

    pubmed:41113119:e0f89798b5ff:e0f89798b5ff

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
  • 28 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (18), assurance_score_below_0.72 (8), current_regulatory_source_required (4), extraction_ambiguity (23), extraction_confidence_not_high (1), high_risk_requires_regulatory_or_two_independent_sources (8), no_direct_support (25)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. ↗

    pubmed · published 2025-11-01 · retrieved 2026-08-29T08:37:13Z

  2. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. ↗

    pubmed · published 2025-12-06 · retrieved 2026-08-29T08:37:13Z

  3. Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials. ↗

    pubmed · published 2026-06-01 · retrieved 2026-08-29T08:37:13Z

Publication history and provenance

Version 2 · Automated assessment · 2026-08-29T08:37:13Z

c5afe09e1d988bd35e75f850f92953979102a6b51f6e4bb025addb16683ff84e